Evidence map›Paper›PMID 35983622›Full record

Trial reportESC heart failure2022

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study.

Takashi Iso, Yuya Matsue, Akira Mizukami, Takashi Tokano, Kikuo Isoda, Satoru Suwa, Katsumi Miyauchi, Naotake Yanagisawa, Yasuo Okumura, Tohru Minamino

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Takashi IsoDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yuya MatsueDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0003-2456-8525
Akira MizukamiDepartment of Cardiology, Kameda Medical Center, Kamogawa, Japan.
Takashi TokanoDepartment of Cardiology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Kikuo IsodaDepartment of Cardiology, Juntendo University Nerima Hospital, Tokyo, Japan.
Satoru SuwaDepartment of Acute Critical Care Medicine, Shizuoka Hospital, Juntendo University, Tokyo, Japan.
Katsumi MiyauchiDepartment of Cardiovascular Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
Naotake YanagisawaMedical Technology Innovation Center, Juntendo University, Tokyo, Japan.
Yasuo OkumuraDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Tohru MinaminoDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Juntendo University · JPJapan Agency for Medical Research and Development · JPJuntendo University Nerima Hospital · JPJuntendo University Shizuoka Hospital · JPJuntendo University Urayasu Hospital · JPKameda Medical Center · JPNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed for the treatment of renal anaemia; however, no study has evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF). This study was designed to evaluate the safety and efficacy of daprodustat, a HIF-PH inhibitor, in patients with HF and renal anaemia. METHODS AND

resultsWe designed a pilot, multi-centre, open-label, randomized controlled study, in which 50 patients with HF complicated with chronic kidney disease and anaemia will be randomized 1:1 to either the daprodustat or control group at seven sites in Japan. Study entry requires New York Heart Association Class II HF symptoms or a history of hospitalization due to HF, an estimated glomerular filtration rate of <60 mL/min/1.73 m

conclusionConsidering the hypothetical upside and downside of using HIF-PH inhibitors in anaemic patients with HF and chronic kidney disease, and because there are virtually no safe and effective treatments for patients with anaemia not caused by iron deficiency, our study results will contribute significantly to this field.

Indexed as

AnemiaHeart FailureRenal Insufficiency, ChronicBarbituratesGlycineHemoglobinsHumansBarbituratesGlycineGSK1278863HemoglobinsAnaemiaChronic kidney diseaseDaprodustatHeart failureHIF-PH inhibitorStudy protocol

Identifiers

PMID35983622
PMCPMC9773652
OpenAlexW4292493669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.